ArticleWorld journal of gastroenterology2012
Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction.
Article in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 20 citations in OpenAlex.
- Characteristics of Successful Third-Line Eradication of Helicobacter pylori based on Antibiotic Susceptibility.Asian Pacific journal of cancer prevention : APJCP · 2025Observational
- Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication ofJournal of clinical medicine · 2023Review
- Sitafloxacin for Third-LineJournal of clinical medicine · 2021Review
- Clinical features of cardiac nodularity-like appearance induced byWorld journal of gastroenterology · 2020Article
- Endoscopic Kyoto classification ofWorld journal of gastroenterology · 2020Review
- World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat.Journal of gastroenterology · 2018Review
- Effects of patient age and choice of antisecretory agent on success of eradication therapy forJournal of clinical biochemistry and nutrition · 2017Article
- Current Paradigm and Future Directions for Treatment of Helicobacter pylori Infection.Current treatment options in gastroenterology · 2014Article
- Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing.Frontiers in molecular biosciences · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the efficacy and tolerability of a dual therapy with rabeprazole and amoxicillin (AMX) as an empiric third-line rescue therapy. In patients with failure of first-line treatment with a proton pump inhibitor (PPI)-AMX-clarithromycin regimen and second-line treatment with the PPI-AMX-metronidazole regimen, a third-line eradication regimen with rabeprazole (10 mg q.i.d.) and AMX (500 mg q.i.d.) was prescribed for 2 wk. Eradication was confirmed by the results of the ¹³C-urea breath test (UBT) at 12 wk after the therapy. A total of 46 patients were included; however, two were lost to follow-up. The eradication rates as determined by per-protocol and intention-to-treat analyses were 65.9% and 63.0%, respectively. The pretreatment UBT results in the subjects showing eradication failure; those patients showing successful eradication comprised 32.9 ± 28.8 permil and 14.8 ± 12.8 permil, respectively. The pretreatment UBT results in the subjects with eradication failure were significantly higher than those in the patients with successful eradication (P = 0.019). A low pretreatment UBT result (≤ 28.5 permil) predicted the success of the eradication therapy with a positive predictive value of 81.3% and a sensitivity of 89.7%. Adverse effects were reported in 18.2% of the patients, mainly diarrhea and stomatitis. Dual therapy with rabeprazole and AMX appears to serve as a potential empirical third-line strategy for patients with low values on pretreatment UBT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.